Sun Pharma has got the Competition Commission of India’s approval to sell the erstwhile Ranbaxy Laboratories’ two divisions in the Central nervous system (CNS) segment in India to Strides Shasun for Rs 165 crore.

The drug major said in a regulatory filing that the company has received an order under the Competition Act, 2002, from the Competition Commission of India (CCI) approving the proposed transaction.

It further added that “With this approval, all necessary regulatory approvals have been obtained.”

Read EquityPandit’s Nifty Pharma Outlook for this week